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A B S T R A C T
Background
When human milk is not available for feeding preterm infants, protein hydrolysate rather than standard cow’s milk formulas (with
intact proteins) are often used because they are perceived as being tolerated better and less likely to lead to complications. However,
protein hydrolysate formulas are more expensive than standard formulas, and concern exists that their use in practice is not supported
by high-quality evidence.
Objectives
To assess the effect of feeding preterm infants with hydrolysed formula (versus standard cow’s milk formulas) on the risk of feed
intolerance, necrotising enterocolitis, and other morbidity and mortality in preterm infants.
Search methods
We used the standard Cochrane Neonatal search strategy including electronic searches of the Cochrane Central Register of Controlled
Trials (CENTRAL; 2017, Issue 4), OvidMEDLINE, Ovid Embase, and the Cumulative Index to Nursing and AlliedHealth Literature
(CINAHL) (to April 2017), as well as conference proceedings and previous reviews.
Selection criteria
Randomised and quasi-randomised controlled trials that compared feeding preterm infants with protein hydrolysate versus standard
(non-hydrolysed) cow’s milk formula.
Data collection and analysis
Two review authors assessed trial eligibility and risk of bias and extracted data independently.We analysed treatment effects as described
in the individual trials and reported risk ratios and risk differences for dichotomous data, andmean differences for continuous data, with
respective 95% conﬁdence intervals (CI). We used a ﬁxed-effect model in meta-analyses and explored potential causes of heterogeneity
in sensitivity analyses. We assessed quality of evidence at the outcome level using the GRADE approach.
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Main results
We identiﬁed 11 trials for inclusion in the review. All trials were small (total participants 665) and had variousmethodological limitations
including uncertainty about methods to ensure allocation concealment and blinding. Most participants were clinically stable preterm
infants of gestational age less than about 34 weeks or birth weight less than about 1750 g. Fewer participants were extremely preterm,
extremely low birth weight, or growth-restricted. Most trials found no effects on feed intolerance assessed variously as mean prefeed
gastric residual volume, incidence of abdominal distention or other concerning gastrointestinal signs, or time taken to achieve full
enteral feeds (meta-analysis was limited because studies used different measures). Meta-analysis found no effect on the risk of necrotising
enterocolitis (typical risk ratio 1.10, 95% CI 0.36 to 3.34; risk difference 0.00, 95% CI -0.03 to 0.04; 5 trials, 385 infants) (low quality
evidence; downgraded for imprecision and design weaknesses).
Authors’ conclusions
The identiﬁed trials provide only low quality evidence about the effects of feeding preterm infants with protein hydrolysate versus
standard formula. The existing data did not support conclusions that feeding with protein hydrolysate affects the risk of feed intolerance
or necrotising enterocolitis. Further large, pragmatic trials are needed to provide more reliable and precise estimates of effectiveness and
cost-effectiveness.
P L A I N L A N G U A G E S U M M A R Y
Hydrolysed formula for preterm infants
Review question: does feeding preterm infants with cow’s milk formula containing predigested (hydrolysed) proteins rather than whole
proteins improve digestion and reduce the risk of severe bowel problems?
Background: preterm infants often ﬁnd cow’s milk formula more difﬁcult to digest than human milk, and cow’s milk formula may
increase the risk of severe bowel problems for preterm (born before their due date) infants. If preterm infants are fed with cow’s milk
formula (when human milk is unavailable), then using a formula in which the protein is already partially digested (called hydrolysed)
rather than a standard formula (with intact proteins) might reduce the risk of these problems. However, hydrolysed formulas are more
expensive than standard formulas, and may have speciﬁc side effects not seen with standard formulas. Given these concerns, we have
reviewed all the available evidence from clinical trials that compared these types of formula for feeding preterm infants.
Study characteristics: in searches of medical databases up to April 2017, we found 11 trials; most were small (involving 665 infants
in total) and had methodological weaknesses.
Key results: the data from these trials provided no strong or consistent evidence that feeding preterm infants with hydrolysed formula
rather than standard formula improved digestion or reduced the risk of severe bowel problems.
Conclusions: the currently available evidence suggested that feeding preterm infants with hydrolysed formula (rather than standard
formula) during their initial hospital admission has no important beneﬁts or harms. However, this ﬁnding is not yet conclusive, and
larger and better quality trials are needed to provide evidence to help clinicians and families make informed choices about this issue.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Hydrolysed compared to non-hydrolysed formula for feeding preterm infants
Patient or population: f eeding preterm infants
Setting: neonatal unit
Intervention: hydrolysed formula (protein hydrolysate)
Comparison: non-hydrolysed formula
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with non-hydrol-
ysed formula
Risk with hydrolysed
Feed intolerance Study populat ion RR 2.71
(0.29 to 25.00)
161
(3 RCTs)
⊕⊕©©
Low
Lim ited data f rom 3
small RCTs with impre-
cise est imate of ef fect
size
13 per 1000 34 per 1000
(4 to 316)
Necrotising enterocol-
itis
Study populat ion RR 1.10
(0.36 to 3.34)
385
(5 RCTs)
⊕⊕©©
Low
Methodological lim ita-
t ions in included tri-
als, and imprecise ef -
fect size est imate
32 per 1000 35 per 1000
(12 to 107)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; RCT: randomised controlled trial; RR: risk rat io.
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B A C K G R O U N D
Hydrolysed cow’s milk formulas, originally developed for infants
with cow’s milk protein allergy or intolerance, are used as enteral
feeding alternatives for preterm infants for whom human milk is
unavailable. These formulas contain hydrolysed rather than intact
proteins, and may also differ from standard cow’s milk formulas in
carbohydrate, lipid, and micronutrient type and content (Oldaeus
1997). Their use as a sole or supplemental enteral feed source for
preterm infants has increased since the late-1990s, particularly in
high-income countries, because they are perceived as being toler-
ated better, and less likely to lead to complications, than standard
cow’s milk formulas (Zuppa 2005). However, hydrolysed formu-
las are more expensive than standard formulas, and concern exists
that their use in practice is not supported by high quality evidence
(Foucard 2005).
Description of the condition
Human breast milk is recommended as the best form of enteral
nutrition for preterm infants (AAP 2012). Breast milk proteins,
carbohydrates, fats, and micronutrients have been optimised by
evolution for neonatal digestion and absorption. Breast milk con-
tains many non-nutrient factors including immunoglobulins and
lactoferrin that promote intestinal adaptation andmaturation, im-
prove enteral feed tolerance, and protect against infection and in-
ﬂammatory disorders (Agostoni 2010; Arslanoglu 2013).
When sufﬁcient human breast milk is unavailable, cow’s milk-
based formulas are used for feeding preterm infants, either as
the sole enteral diet or as a supplement to human breast milk
(Klingenberg 2012). Feeding preterm infants with standard cow’s
milk formulas rather than human breast milk is, however, as-
sociated with higher rates of feed intolerance and necrotising
enterocolitis (Quigley 2014). Feed intolerance and interruption
of enteral feeds is a major contributor to cumulative nutrient
deﬁcits and postnatal growth restriction in very preterm infants
(Embleton 2001; Cooke 2016). Slow postnatal growth is associ-
ated with neurodevelopmental impairment in later childhood and
with poorer cognitive and educational outcomes (Brandt 2003;
Embleton 2013a; Leppanen 2014). Necrotising enterocolitis af-
fects about 5%of very preterm infants. Infants who develop necro-
tising enterocolitis experience more infections, have lower levels
of nutrient intake, grow more slowly, have longer durations of
intensive care and hospital stay, and are more likely to die or be
disabled than gestation-comparable infants who do not develop
necrotising enterocolitis (Morgan 2011; Pike 2012; Yee 2012).
Description of the intervention
Standard cow’s milk formulas can be grouped broadly as ’term’
formulas (designed for term infants; nutrient content based on
the composition of mature breast milk) and nutrient-enriched
’preterm’ formulas (designed for preterm or low birth weight
infants; energy-enriched and variably protein- and mineral-en-
riched) (Fewtrell 1999). Concern exists that standard cow’s milk
formulas (either ’term’ or ’preterm’) are poorly tolerated, especially
by very preterm infants, because the immature infant’s gastroin-
testinal tract is less efﬁcient than that of term infants at digesting
intact cow’s milk proteins and fats (Ewer 1994; Lindberg 1998).
Hydrolysed formulas
’Hydrolysed’ protein formulas, containing protein digested chem-
ically (acid/alkali) or enzymatically (protease) to oligopeptides,
are often used for feeding preterm infants, especially infants with
feed intolerance or clinical features (such as episodic apnoea, oxy-
gen desaturation or bradycardia) that are attributed to gastro-oe-
sophageal reﬂux, or following gastrointestinal surgery or necrotis-
ing enterocolitis (Zuppa 2005).
Several brands of hydrolysed formulas (both ’term’ and ’preterm’)
are available commercially and these are grouped broadly depend-
ing on degree of hydrolysis:
• extensively hydrolysed: residual free amino acids and
peptides with molecular weights less than 1.5 kDa to 3.0 kDa;
• partially hydrolysed: residual peptides with molecular
weights of 3.0 kDa to 10.0 kDa.
This distinction is mainly relevant to the putative hypo-allergenic
properties of hydrolysed formulas and there are limited data re-
garding its functional relevance to preterm infants. Formulas also
vary by the predominant protein source (casein versus whey-ca-
sein) as well as by carbohydrate (lactose, maltodextrin) and fat
(cow, vegetable) type and content (BNFC 2016).
How the intervention might work
Although developed as hypo-allergenic alternatives to standard
cow’s milk formulas for infants at risk of cow’s milk protein in-
tolerance or allergy, the evidence for this effect in term infants is
very weak (Boyle 2016; Osborn 2017). In preterm infants, hy-
drolysed formulas are mostly used for their perceived beneﬁts in
reducing the risk of feed intolerance and necrotising enterocolitis.
When human milk is unavailable, hydrolysed formulas may be
used empirically (starter formula) or therapeutically to improve
feeding tolerance or reduce gastro-oesophageal reﬂux. The possi-
ble mechanisms for these effects include accelerated gastric empty-
ing and intestinal transit, more efﬁcient enteric peptide digestion,
and stimulation of small intestinal enzymatic and motilin activity
(Mihatsch 2001b; Zuppa 2005). If better feed tolerance reduces
the time taken to establish full enteral feeding in very preterm
infants, this may reduce the adverse infectious or metabolic con-
sequences of prolonged exposure to parenteral nutrition.
Several potential adverse effects of hydrolysed formulas are recog-
nised.Osmolality increaseswhenprotein is hydrolysed into smaller
peptides, and these higher osmolarity ﬂuids delivered to the small
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intestinemay increase the risk of necrotising enterocolitis. Further-
more, if bioactive proteins such as immunoglobulin or lactoferrin
are hydrolysed, this may reduce their putative beneﬁts in reducing
the risk of infection or necrotising enterocolitis. It is possible that
some peptides created by artiﬁcial hydrolysis have diminished or
harmful functional activities (Embleton 2013b). Concern about
micronutrient bioavailability in hydrolysed formulas also exists,
particularly whether bone minerals are less well absorbed in the
absence of intact casein proteins (Zuppa 2005).
Why it is important to do this review
Given the potential for protein hydrolysate formulas (rather than
standard cow’s milk formulas) to improve enteral feed tolerance
and prevent adverse outcomes in preterm infants, we undertook
a systematic review of the randomised trial data to help to inform
practice and research.
O B J E C T I V E S
To assess the effect of feeding preterm infants with hydrolysed for-
mula (versus standard cow’s milk formulas) on the risk of feed in-
tolerance, necrotising enterocolitis, and other morbidity and mor-
tality in preterm infants.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised or quasi-randomised controlled trials, including clus-
ter-randomised controlled trials.
Types of participants
Preterm (less than 37 weeks’ gestation) newborn infants who re-
ceived cow’s milk formula as their sole or supplemental enteral
diet.
Types of interventions
Hydrolysed cow’s milk formula versus standard (non-hydrolysed)
cow’s milk formula or another type of hydrolysed cow’s milk for-
mula. Formula was to be allocated as at least 20% of intended
enteral diet for at least two weeks to allow measurable effects on
growth rates and episodes of feed intolerance. Trials should have
compared formulas with similar energy and protein levels (i.e. hy-
drolysed ’preterm’ formula versus non-hydrolysed ’preterm’ for-
mula, or hydrolysed ’term’ formula versus non-hydrolysed ’term’
formula).
We planned separate comparisons of trials that assessed:
• empirical use of hydrolysed formulas;
• indicated (therapeutic) use of hydrolysed formulas to treat
infants with feed intolerance, gastro-oesophageal reﬂux (and
associated apnoea, desaturation or bradycardia), or following
gastrointestinal surgery or necrotising enterocolitis (as deﬁned by
the primary investigators).
Types of outcome measures
Primary outcomes
• Number of infants with at least one episode of feed
intolerance that resulted in cessation or reduction in enteral
feeding (enteral feeds reduced or ceased for more than four
hours), or mean number of episodes of feed intolerance during
trial period, or both.
• Infants with at least one episode of necrotising enterocolitis
(modiﬁed Bell stage 2/3) (Walsh 1986) (unless indicated use
following necrotising enterocolitis).
Secondary outcomes
• Time to full enteral feeding independent of parenteral
ﬂuids (days).
• Growth: time to regain birth weight, and subsequent rates
of weight (grams/kilogram/day), length (millimetre/week), and
head growth (millimetre/week) during hospital admission.
• Duration of hospital admission (days).
• Measures of bone mineralisation:
◦ serum alkaline phosphatase level at 36 to 40 weeks’
postmenstrual age or
◦ bone mineral content assessed post-term by dual
energy x-ray absorptiometry (DEXA) or
◦ clinical or radiological evidence of rickets on long-
term follow-up.
• Late-onset invasive infection diagnosed more than 72 hours
after birth as determined by culture from a normally sterile site:
cerebrospinal ﬂuid, blood, bone or joint, peritoneum, pleural
space or central venous line tip; or ﬁndings on autopsy
examination consistent with invasive microbial infection.
• Mortality: all-cause until 28 days and during hospital
admission.
• Neurodevelopmental outcomes assessed by a validated test
after 12 months’ post-term: neurological evaluations,
developmental scores and classiﬁcations of disability, including
auditory and visual disability.
• Allergy or atopy diagnosed after 12 months’ post-term:
asthma, eczema, allergic rhinitis or conjunctivitis, food allergy,
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allergic sensitisation (skin prick, or speciﬁc or total
immunoglobulin E level) (Boyle 2016).
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Tri-
als (CENTRAL, 2017, issue 4), Ovid MEDLINE (1946 to April
2017), Ovid Embase (1974 to April 2017), Ovid Maternity &
Infant Care Database (1971 to April 2017), and CINAHL (1982
to April 2017) using a combination of the following text words
and MeSH terms described in Appendix 1. We limited the search
outputs with the relevant search ﬁlters for clinical trials as recom-
mended in the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Higgins 2011). We did not apply any language restric-
tions.
We searched ClinicalTrials.gov and the World Health Organiza-
tion’s International Trials Registry and Platform (www.who.int/
ictrp/en/) for completed or ongoing trials.
Searching other resources
We examined reference lists in previous reviews and included stud-
ies. We searched the proceedings of the annual meetings of the
Pediatric Academic Societies (1993 to 2016), the European So-
ciety for Paediatric Research (1995 to 2016), the Royal College
of Paediatrics and Child Health (2000 to 2017) and the Perina-
tal Society of Australia and New Zealand (2000 to 2016). Trials
reported only as abstracts were eligible if sufﬁcient information
was available from the report, or from contact with the authors,
to fulﬁl the inclusion criteria.
Data collection and analysis
We used the standard methods of Cochrane Neonatal.
Selection of studies
We screened the title and abstract of all studies identiﬁed by the
search strategy and two review authors independently assessed the
full articles for all potentially relevant trials. We excluded those
studies that did not meet all the inclusion criteria and we stated
the reason for exclusion. We discussed any disagreements until
consensus was achieved.
Data extraction and management
Two review authors (DN and WM) extracted data independently
using a data collection form to aid extraction of information on
design, methodology, participants, interventions, outcomes and
treatment effects from each included study. We discussed any dis-
agreements until we reached a consensus. If data from the trial
reports were insufﬁcient, we contacted the trialists for further in-
formation.
Assessment of risk of bias in included studies
We used the criteria and standard methods of Cochrane Neonatal
to assess the methodological quality of any included trials. Two
review authors (DN and JKA) assessed risk of bias across key do-
mains (Appendix 2) and resolved disagreements in consultation
with a third review author (WM). We requested additional infor-
mation from the trial authors to clarify methodology and results
when necessary. We did not exclude trials on the basis of risk of
bias, but we did plan to conduct sensitivity analyses if applicable
to explore the consequences of synthesising evidence of variable
quality (Higgins 2011).
Measures of treatment effect
We analysed the treatment effects in the individual trials using
Review Manager 5 (RevMan 2014) and reported risk ratio (RR)
and risk difference (RD) for dichotomous data and mean differ-
ence (MD) for continuous data, with respective 95% conﬁdence
intervals (CI). We determined the number needed to treat for an
additional beneﬁcial outcome (NNTB) or an additional harmful
outcome (NNTH) for analyses with a statistically signiﬁcant dif-
ference in the RD.
Unit of analysis issues
The unit of analysis was the participating infant in individually
randomised trials and the neonatal unit (or subunit) for cluster-
randomised trials. For cluster-randomised trials, we planned to
undertake analyses at the level of the participant while accounting
for the clustering in the data using the methods recommended
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011).
Dealing with missing data
Where data were missing, and could not be derived as described,
we approached the analysis of missing data as follows.
• We contacted the original study investigators to request the
missing data.
• Where possible, we imputed missing standard deviations
(SDs) using the coefﬁcient of variation (CV) or calculated from
other available statistics including standard errors, CIs, t values
and P values.
• If the data were assumed to be missing at random, we
analysed the data without imputing any missing values.
• If this could not be assumed, then we planned to impute
the missing outcomes with replacement values, assuming all to
have a poor outcome. We planned sensitivity analyses to assess
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any changes in the direction or magnitude of effect resulting
from data imputation.
Assessment of heterogeneity
Two review authors assessed clinical heterogeneity, with a meta-
analysis conducted only when both authors agreed that study par-
ticipants, interventions and outcomes were sufﬁciently similar.
We examined the treatment effects of individual trials and het-
erogeneity between trial results by inspecting the forest plots. We
calculated the I² statistic for each analysis to quantify inconsis-
tency across studies and described the percentage of variability in
effect estimates that may be due to heterogeneity rather than to
sampling error. If we detected moderate or high heterogeneity (I²
greater than 50%), we would explore the possible causes (e.g. dif-
ferences in study design, participants, interventions or complete-
ness of outcome assessments).
Assessment of reporting biases
If more than 10 trials were included in ameta-analysis, we planned
to examine a funnel plot for asymmetry.
Data synthesis
We used the ﬁxed-effect model in Review Manager 5 for meta-
analyses (as per Cochrane Neonatal recommendations) (RevMan
2014).Wheremoderate or high heterogeneity existed, we planned
to examine the potential causes in subgroup and sensitivity anal-
yses.
Quality of evidence
We assessed the quality of evidence for themain comparisons at the
primary outcomes level using the GRADE approach, as outlined
in the GRADE handbook (Schünemann 2013; see Appendix 3).
Two review authors independently assessed the quality of the evi-
dence for outcomes identiﬁed as critical or important for clinical
decision-making (feed tolerance and incidence of necrotising en-
terocolitis). We considered evidence from randomised controlled
trials as high quality but downgraded the evidence one level for
serious (or two levels for very serious) limitations based upon the
following: design (risk of bias), consistency across studies, direct-
ness of the evidence, precision of estimates and presence of pub-
lication bias. We used the GRADEpro GDT Guideline Develop-
ment Tool to create a ’Summary of ﬁndings’ table to report the
quality of the evidence.
Subgroup analysis and investigation of heterogeneity
We planned subgroup analyses by:
• gestational age at birth: very preterm (less than 32 weeks)
infants versus infants born at 32 weeks or later;
• indication (for therapeutic use): postsurgery versus
postnecrotising enterocolitis versus feeding intolerance or gastro-
oesophageal reﬂux;
• extent of protein hydrolysis (as deﬁned by manufacturers):
extensively versus partially hydrolysed formula.
Sensitivity analysis
We planned sensitivity analyses to determine if the ﬁndings were
affected by including only studies of adequate methodology (low
risk of bias), deﬁned as adequate randomisation and allocation
concealment, blinding of intervention and measurement, and less
than 10% loss to follow-up.
R E S U L T S
Description of studies
Results of the search
From the preliminary search, we identiﬁed 1405 records, includ-
ing three records from other sources. After removing duplicates,
we screened 805 separate records against titles and abstracts for rel-
evance. Among these, we excluded 782 articles outright.We short-
listed 21 articles for full-text assessment, with two articles identi-
ﬁed as on-going trials (ACTRN12613000481774; Yin 2015).
We included 11 trials (Characteristics of included studies table)
and excluded seven studies (Characteristics of excluded studies
table). See Figure 1.
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Figure 1. Study flow diagram.
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One trial is awaiting further data (Del Moral 2017), and two trials
await English language translation to allow assessment of eligibility
for inclusion (Dobryanskyy 2015; Luo 2016).
Included studies
We included 11 trials (Huston 1992; Schweizer 1993; Raupp
1995; Pauls 1996; Picaud 2001; Riezzo 2001; Mihatsch 2002;
Szajewska 2004;Maggio 2005; Florendo 2009; Baldassarre 2017).
Most of the included trials were undertaken during the 1990s
and 2000s by investigators in neonatal units in Europe (mainly
Germany and Italy) and North America. For further details, see
Characteristics of included studies table.
Participants
In total, 665 infants participated in the included trials. Most par-
ticipants were clinically stable preterm infants of gestational age
less than about 34 weeks or birth weight less than about 1750
g. Few participants were extremely preterm, extremely low birth
weight or growth-restricted.Most of the trials speciﬁcally excluded
infants with congenital anomalies, or gastrointestinal or neurolog-
ical problems.
Interventions
All the trials assessed the empirical use of protein hydrolysate for-
mulas; none assessed indicated use.
Trials varied according to brandof formula studied. All trials except
one assessed a “preterm” (nutrient-enriched) hydrolysed formula;
Schweizer 1993 assessed a “term” hydrolysed formula. Most trials
used a whey-casein-based hydrolysate. Two trials used a predom-
inantly casein-based hydrolysate (Huston 1992; Riezzo 2001).
Most studies assessed a partially hydrolysed formula. Three trials
use an extensively hydrolysed formula (Schweizer 1993; Mihatsch
2002; Baldassarre 2017).One (three-arm) trial randomly allocated
infants to receive a partially hydrolysed formula, an extensively
hydrolysed formula, or a standard preterm formula (Szajewska
2004). Control diets were preterm non-hydrolysed formulas in all
except Riezzo 2001 where the control diet was a standard term
formula.
No trials compared hydrolysed cow’s milk formula versus another
type of hydrolysed cow’s milk formula.
Trial participants received the intervention or control formulas on
commencing enteral feeds either as a sole diet or a supplement
when mother’s own milk was not available or insufﬁcient. One
trial speciﬁcally excluded participants post hoc if mother’s own
milk formed more than 10% of enteral intake (Mihatsch 2002).
In general, trial feeds were allocated for several weeks (at least two
weeks), or until participating infants reached a speciﬁed weight
(typically about 1.8 kg).
Outcomes
The outcomes reportedmost commonly were feed intolerance (re-
ported in variousways but oftenwithout accompanying numerical
data), growth parameters during the study period or until hospital
discharge, and adverse events (including mortality and necrotising
enterocolitis). None of the trials reported long-term growth and
neurodevelopmental outcomes.
Excluded studies
Weexcluded seven studies (Rigo 1994;Rigo 1995;Mihatsch 1999;
Mihatsch 2001a; Agosti 2003; Corvaglia 2013; Logarajaha 2015).
The reasons for exclusion are described in the Characteristics of
excluded studies table.
Risk of bias in included studies
Quality assessments are detailed in the Characteristics of included
studies table and summarised in Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Three trials reported adequate allocation concealment methods
(sealed, numbered envelopes; central randomisation in blocks) and
were at low risk of bias (Szajewska 2004; Maggio 2005; Florendo
2009). None of the remaining trials reported sufﬁcient details to
assess if or how allocation concealment was achieved.
Blinding
Four trials reported blinding of investigators, and carers or parents (
Schweizer 1993;Maggio 2005; Florendo 2009; Baldassarre 2017).
It is probable that the other trials were not blinded as the reports
did not describe any methods that might achieve this.
Incomplete outcome data
Most trials were likely to be at low risk of bias because of incom-
plete assessment of the trial cohort. In one trial, the investigators
recruited 129 infants initially then excluded 42 participants post
hoc because they had received more than 10% of their enteral in-
take as human milk (Mihatsch 2002).
Selective reporting
We were unable to assess reliably whether selective reporting oc-
curred as we did not have protocols or other indicators of prespec-
iﬁed outcomes for any of the trials.
Other potential sources of bias
We did not identify any other potential sources of bias in the
reports.
Effects of interventions
See: Summary of findings for the main comparisonHydrolysed
compared to non-hydrolysed formula for feeding preterm infants
Empirical use of protein hydrolysate versus standard
formula (Comparison 1)
1. Feed intolerance (Outcome 1.1)
Two trials reported numerical data on the incidence of feed intol-
erance (Maggio 2005; Florendo 2009; Baldassarre 2017). Meta-
analysis found no statistically signiﬁcant effect (typical RR 2.71,
95% CI 0.29 to 25.00; typical RD 0.02, 95% CI -0.03 to 0.08)
(I² not applicable) (Analysis 1.1).
The other trials did not report any numerical data but described
their ﬁndings narratively. These found no differences in mea-
sures of gastric residual volumes (Pauls 1996;Mihatsch 2002), fre-
quency of regurgitation (Riezzo 2001), or vomiting or diarrhoea
(Szajewska 2004). Raupp 1995 reported that “both formulas were
well tolerated.” The remaining trials did not report any measures
of feed intolerance (Huston 1992; Schweizer 1993; Picaud 2001).
2. Incidence of necrotising enterocolitis (Outcome 1.2)
Meta-analysis of data from ﬁve trials (385 infants) found no dif-
ference (typical RR 1.10, 95% CI 0.36 to 3.34; typical RD 0.00,
95% CI -0.03 to 0.04) (I² = 0%) (Analysis 1.2; Figure 3).
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Figure 3. Forest plot of comparison: 1 Hydrolysed versus non-hydrolysed formula, outcome: 1.2 Necrotising
enterocolitis.
The other trials did not report this outcome, although in most it
seems likely that none of the participants developed necrotising
enterocolitis.
The quality of evidence for the primary outcomes was low because
of methodological limitations in the included trials (including un-
certainty about allocation concealment and blinding), and impre-
cision of effect size estimates (Summary of ﬁndings for the main
comparison).
3. Time to full enteral feeding (Outcome 1.3)
Most trials did not report time to full enteral feeds (Huston
1992; Raupp 1995; Riezzo 2001; Szajewska 2004; Maggio 2005;
Florendo 2009).
Mihatsch 2002 reported that the median time to full enteral feed-
ing was shorter in the intervention group (10 days versus 12 days
in the control group).
Four trials reported no difference:
• Schweizer 1993: 24 days versus 25 days (SD not reported);
• Pauls 1996; no data reported;
• Picaud 2001: 16 (SD 8) days versus 17 (SD 8) days (MD
-1.00 days, 95% CI -8.36 to 6.36).
• Baldassarre 2017: 11 days versus 10 days (SD not reported)
4. Growth: time to regain birth weight, and subsequent rates
of growth during hospital admission (Outcomes 1.4 to 1.6)
Four trials did not report any growth data (Pauls 1996; Riezzo
2001; Szajewska 2004; Baldassarre 2017). The other trials reported
some data on growth parameters during the study period or until
hospital discharge, but most did not provide sufﬁcient data for
inclusion in the meta-analysis (Huston 1992; Schweizer 1993;
Raupp 1995; Mihatsch 2002).
Time to regain birth weight
One trial reported days to regain birth weight (Schweizer 1993).
This trial found no difference (10 days in the intervention group
versus 9 days in the control group; SD not reported).
Weight gain
Three trials reported rates of weight gain over the study period
or until hospital discharge (Picaud 2001; Maggio 2005; Florendo
2009). Meta-analysis showed that weight gain was slower in the
infants fed with hydrolysed formula (MD -3.02 g/kg/day, 95%CI
-4.66 to -1.38) (Analysis 1.4; Figure 4).
12Protein hydrolysate versus standard formula for preterm infants (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 4. Forest plot of comparison: 1 Hydrolysed versus non-hydrolysed formula, outcome: 1.4 Weight
gain (g/kg/day).
Length change
Meta-analysis of data from two trials (97 infants) found no dif-
ference in length change (MD -0.04 mm/week, 95% CI -1.24 to
1.15) (Analysis 1.5).
Head circumference growth
Meta-analysis of data from two trials (97 infants) found no dif-
ference in head circumference growth (MD 0.27 mm/week, 95%
CI -0.39 to 0.94) (Analysis 1.6).
5. Duration of hospital admission
None of the trials reported the duration of hospital admission.
6. Measures of bone mineralisation (Outcome 1.7)
Two trials reportedmeasures of bone mineralisation (Raupp 1995;
Florendo 2009). Neither trial, nor a meta-analysis of data from
both trials, showed a difference in serum alkaline phosphatase level
at 36 to 40 weeks’ postmenstrual age (MD 16.6 IU/L, 95% CI
-34.1 to 67.4) (Analysis 1.7; Figure 5). None of the trials reported
bone mineral content assessed post-term or clinical or radiological
evidence of rickets on long-term follow-up.
Figure 5. Forest plot of comparison: 1 Hydrolysed versus non-hydrolysed formula, outcome: 1.7 Serum
alkaline phosphatase (IU/L).
7. Late-onset invasive infection (Outcome 1.8)
Only one trial reported the incidence of late-onset invasive in-
fection (Baldassarre 2017). There was no difference in the in-
cidence of microbiologically conﬁrmed bacteraemia (typical RR
1.50, 95% CI 0.27 to 8.34; typical RD -0.03, 95% CI -0.11 to
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0.17) (Analysis 1.8).
8. Mortality
None of the trials reported the incidence of mortality.
9. Neurodevelopmental outcomes
None of the trials reported neurodevelopmental outcomes.
10. Allergy or atopy diagnosed after 12 months’ post-term
(Outcome 1.8)
One trial assessed allergy or atopy (Szajewska 2004). The trial
found no difference in the incidence of “any allergic disease”
(atopic dermatitis, gastrointestinal symptoms, wheezing) at 12
months (RR 0.62, 95% CI 0.27 to 1.42; RD -0.13, 95% CI -0.36
to 0.10) (Analysis 1.9).
Subgroup analyses
• Gestational age at birth: very preterm (less than 32 weeks)
infants versus infants born at 32 weeks or later: subgroup data
not available.
• Indication (for therapeutic use): postsurgery versus post-
necrotising enterocolitis versus feeding intolerance or gastro-
oesophageal reﬂux: not applicable as all trials assessed empirical
use.
• Extent of protein hydrolysis (as deﬁned by manufacturers):
data for subgroup analysis sufﬁcient for necrotising enterocolitis
(outcome 1.2) only. Three trials used a partially hydrolysed
preterm formula (Raupp 1995; Pauls 1996; Florendo 2009).
Two trials used an extensively hydrolysed formula (Mihatsch
1999; Baldassarre 2017). Meta-analysis found no evidence of a
subgroup effect (test for subgroup differences: Chi² = 0.75, df =
1 (P = 0.39), I² = 0%) (Figure 3).
Indicated use of protein hydrolysate versus standard
formula (Comparison 2)
We found no trials comparing protein hydrolysate versus standard
formula.
D I S C U S S I O N
Summary of main results
These data from 11 small randomised controlled trials provided
only low quality evidence about how feeding preterm infants (typ-
ically stable infants of gestational age less than 34 weeks at birth)
with protein hydrolysate rather than standard cow’s milk formula
affects the risk of feed tolerance, necrotising enterocolitis or other
adverse outcomes. Limited data did not indicate any important ef-
fects on growth, although a meta-analysis of data from three trials
suggested that weight gain was slower in infants fed with protein
hydrolysate compared with isocaloric preterm formula. There are
currently no data available to assess the effects on growth and neu-
rodevelopmental outcomes beyond the initial hospital admission.
Overall completeness and applicability of
evidence
These ﬁndings should be interpreted and applied cautiously. The
primary outcome, feed intolerance, was reported in various ways,
and together with the paucity of numerical data, this precluded
meta-analysis. Trials generally reported that feeding with protein
hydrolysate did not affect measures such as the prefeed gastric
residual volume or the need to cease enteral feeding. Similarly, few
trials reported the impact of the interventionon the time to achieve
full enteral feeding, and the trials that did report this outcome
found no statistically signiﬁcant or clinically important effects.
Although a meta-analysis of ﬁve trials (385 participants) found no
effect on the risk of necrotising enterocolitis, there were insufﬁ-
cient data to exclude a more modest but still important effect size.
The lower bound of the 95% CI was consistent with a 3% ab-
solute risk reduction (i.e. one fewer infant developing necrotising
enterocolitis for every 33 infants who received protein hydrolysate
formula). Because necrotising enterocolitis is a relatively rare out-
come, affecting about 5% of very preterm infants, much larger
trials would be needed to provide a more precise estimate of the
effect of feeding with protein hydrolysate versus standard formula
(Yee 2012).
Data on growth parameters are limited, as are data on other adverse
outcomes. Furthermore, uncertainty remains about longer-term
impact on growth or development. As concerns exist that hydrol-
ysed proteins may be utilised less efﬁciently than intact proteins
by preterm infants, and that concomitant mineral uptake may be
lower, trials that assess the effects on both short- and long-term
growth and body composition (including bone health) may help
to inform policy and practice (Senterre 2016).
Another major applicability limitation of this review is that all
the included trials were undertaken at healthcare facilities in high-
income countries, and none in low-income countries. Therefore,
this evidence may be of limited applicability to practices in re-
source-limited settingswhere, globally,most preterm and lowbirth
weight infants are cared for (Imdad 2013).
All the included trials assessed the effect of empirical (primary) use
of protein hydrolysate for feeding preterm infants. We found no
trials that assessed the indicated use of protein hydrolysate versus
standard formula for preterm infants with feed intolerance, gastro-
oesophageal reﬂux (and associated apnoea, desaturation or brady-
cardia), or following gastrointestinal surgery or necrotising entero-
colitis. Although indicated use of protein hydrolysate is common,
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based on perceptions that formulas with intact proteins may be
tolerated poorly by infants with intestinal trauma or compromise,
there is no evidence from trials to inform this practice (Lapillonne
2016).
Quality of the evidence
The GRADE assessments indicated that the quality of evidence
for the primary outcomes was ’low’ because of methodological
limitations in the included trials (including uncertainty about al-
location concealment and blinding), and imprecision of effect size
estimates (Summary of ﬁndings for the main comparison).
Most of the included trials were funded or supported by the man-
ufacturers of the formulas being assessed but the funders were not
involved in trial design or analysis. However, there remains some
concern that formula manufacturers may promote study ﬁndings
of trials of specialist formulas selectively as part of a marketing
strategy that subverts UNICEF Baby Friendly Initiative regula-
tions (Cleminson 2015).
Potential biases in the review process
It is possible that our ﬁndings were subject to publication and
other reporting biases. We attempted to minimise this by screen-
ing the reference lists of included trials and related reviews and
searching the proceedings of major international perinatal confer-
ences to identify trial reports that were not (or were not yet) pub-
lished in full form in academic journals. The meta-analyses that
we performed did not contain sufﬁcient trials to explore symmetry
of funnel plots as a means of identifying possible publication or
reporting bias.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review provides only low quality evidence regarding any ben-
eﬁts or harms of feeding preterm infants with protein hydrolysate
versus standard formula. Although there are no trial data to sug-
gest an effect on the risk of feed intolerance or necrotising entero-
colitis, the total number of infants studied was small (665 infants)
and the data that could be abstracted from published studies for
inclusion in meta-analyses were limited.
Implications for research
Further, high-quality randomised controlled trials are needed to
assess the beneﬁts and safety of protein hydrolysate versus stan-
dard cow’s milk formulas for feeding very preterm infants when
maternal breast milk is insufﬁcient or not available. Trials could
assess primary (empirical) use and secondary (indicated) use in
infants with feed intolerance or gastro-oesophageal reﬂux, or fol-
lowing gastrointestinal surgery or necrotising enterocolitis. Trials
should aim to ensure the participation of extremely preterm, ex-
tremely low birth weight or growth-restricted infants so that sub-
group analyses can be planned for these infants at higher risk of
necrotising enterocolitis. Given that protein hydrolysate preterm
formulas is more expensive than standard preterm formula, trials
could justiﬁably include a cost-beneﬁt analysis.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Baldassarre 2017
Methods RCT.
Participants Preterm infants (28-33 weeks’ gestational age; birth weight 700-1750 g and appropriate
to gestational age), within 24 hours of ﬁrst enteral feeding (and whose mother did not
plan to exclusively breastfeed)
Interventions Extensively hydrolysed casein infant formula (n = 33).
Standard cow’s milk-based preterm infant formula (n = 35).
Outcomes Enteral intake (ml/kg/day) during ﬁrst 14 days after birth.
Feeds intolerance measures (abdominal distention, regurgitation/emesis, feedings with-
held ≥ 4 hours or bloody stools)
Necrotising enterocolitis.
Invasive infection.
Notes University of Bari-Policlinico Hospital, Neonatology and Neonatal Intensive Care Unit,
Department of Biomedical Science and Human Oncology, Bari, Italy
Trial date: 2014-2016.
Trial registration: clinicaltrials.gov/ct2/show/NCT01987154.
Further information provided by investigators (August 2017).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated.
Allocation concealment (selection bias) Low risk Sealed opaque envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double-blind.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Double-blind.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 60/68 enrolled infants completed trial and contributed to out-
come analysis
Selective reporting (reporting bias) Unclear risk Protocol not available.
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Baldassarre 2017 (Continued)
Other bias Unclear risk Funded by Mead Johnson Nutrition.
Florendo 2009
Methods RCT.
Participants Preterm infants (≤ 32 weeks’ gestational age,≤ 1750 g at birth) receiving ≤ 25% breast
milk as total enteral intake
Interventions Empirical use of partially hydrolysed whey-casein preterm formula (n = 42)
Intact preterm formula (n = 38).
Outcomes Feed intolerance (interruption of enteral feeds).
Necrotising enterocolitis.
Notes Division of Neonatology, University of Tennessee Center for Health Sciences, Memphis,
TN, USA
Trial date: 2004-2005.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated.
Allocation concealment (selection bias) Low risk Sequentially labelled, sealed opaque envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double-blind,” ready-to-feed colour coded cartons.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Double-blind.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Complete outcome data for 74/80 participants.
1 infant in the control group developed sepsis and 1 infant from
the hydrolysed formula group developed necrotising enterocol-
itis and was withdrawn
Selective reporting (reporting bias) Unclear risk Protocol not available.
Other bias Unclear risk Funded by Nestle (manufacturer of the trial formula).
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Huston 1992
Methods RCT.
Participants Preterm very low birth weight infants.
Interventions Empirical use of partially hydrolysed casein hydrolysate formula (with either 40% or
60% medium chain triglyceride)
Non-hydrolysed preterm formula.
Total n = 60.
Outcomes Food tolerance.
Growth rates.
Notes Department of Pediatrics, Emanual Children’s Health Care Centre, Portland, OR, USA
Trial date: early 1990s.
Reported as abstract only.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufﬁcient information - only abstract available.
Allocation concealment (selection bias) Unclear risk Insufﬁcient information - only abstract available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unlikely to be blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Unlikely to be blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcomes reported for all participants.
Selective reporting (reporting bias) Unclear risk Protocol not available.
Other bias Unclear risk Funder: Mead Johnson Nutritional Group.
Maggio 2005
Methods RCT.
Participants Preterm infants (≤ 34 weeks’ gestational age, ≤ 1750 g at birth)
Interventions Empirical use of partially hydrolysed whey-based formula* (n = 10)
Conventional preterm formula* (n = 11).
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Maggio 2005 (Continued)
Outcomes Growth rates from inclusion until hospital discharge.
Feed intolerance (no infants had enteral feeds interrupted).
Notes Division of Neonatology, Department of Paediatrics, Catholic University of the Sacred
Heart, Rome, Italy
Trial date: 1998-2000.
* Energy content of both formulas: 75 kCal/100 mL.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised schedule generated - not speciﬁed how.
Allocation concealment (selection bias) Low risk Sealed opaque envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study and control formulas identical in colour and smell.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Study and control formulas identical in colour and smell.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcomes reported for all participants.
Selective reporting (reporting bias) Unclear risk Protocol not available.
Other bias Unclear risk Funded by Humana (manufacturer of the trial formula).
Mihatsch 2002
Methods RCT.
Participants Very low birth weight (< 1500 g) infants.
Interventions Empirical use of extensively hydrolysed (whey-casein) preterm formula* (n = 41)
Standard preterm formula* (n = 46).
Outcomes Necrotising enterocolitis.
Proportion of enteral feeds with gastric residual volumes > 5 mL/kg birth weight
Notes Division of Neonatology and Pediatric Critical Care, Department of Pediatrics, Ulm
University, 89070 Ulm, Germany
Trial date: 1999-2001.
* Energy content of both formulas: 80 kCal/100 mL.
22Protein hydrolysate versus standard formula for preterm infants (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Mihatsch 2002 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated.
Allocation concealment (selection bias) Unclear risk Sealed envelopes - unclear if opaque.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Double-blind”- same appearance, but investigators acknowl-
edged taste different
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Double-blind.”
Incomplete outcome data (attrition bias)
All outcomes
High risk 129 infants recruited initially, then 42 excluded post hoc because
they received > 10% of enteral intake as human milk
Selective reporting (reporting bias) Unclear risk Protocol not available.
Other bias Unclear risk Funder: Milupa GmbH, Germany (manufacturer of the trial
formula)
Pauls 1996
Methods RCT.
Participants Very low birth weight (< 1500 g) infants.
Interventions Empirical use of partially hydrolysed whey-casein formula* (n = 25)
Non-hydrolysed protein formula* (n = 25).
Outcomes Mean gastric residual volume (% of intake).
Time to full enteral feeds.
Necrotising enterocolitis.
Notes Kinderklinik, Freie Universitat Berlin, Germany.
Trial date: early 1990s.
Reported as an abstract only.
* Energy content of both formulas: 80kCal/100mL; protein content: hydrolysed formula
2.9 g/100 mL vs non-hydrolysed formula 2.7 g/100 mL
Risk of bias
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Pauls 1996 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufﬁcient information - only abstract available.
Allocation concealment (selection bias) Unclear risk Insufﬁcient information - only abstract available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unlikely to be blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Unlikely to be blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcomes reported for all participants.
Selective reporting (reporting bias) Unclear risk Protocol not available.
Other bias Unclear risk Funder: not stated.
Picaud 2001
Methods RCT.
Participants Preterm newborns with birth weight < 1500 g and aged < 15 days old when commencing
enteral feeds
Interventions Empirical use of partially hydrolysed formula* (n = 9).
Standard preterm formula* (n = 7).
Until 40 weeks’ postmenstrual age.
Outcomes Rate of weight gain during initial hospital admission.
Nitrogen balance studies.
Notes Edouard Herriot Hospital, Claude Bernard University, Lyon, France
Trial date: late 1990s.
* Energy content of both formulas: 80 kCal/100 mL, but nitrogen content 10% higher
in standard preterm formula
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated.
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Picaud 2001 (Continued)
Allocation concealment (selection bias) Unclear risk Sealed envelopes - unclear if opaque.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Investigators unaware of formula, unclear if carers or parents
aware
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Investigators unaware of formula, unclear if carers or parents
aware
Incomplete outcome data (attrition bias)
All outcomes
Low risk All infants assessed for primary outcomes.
Selective reporting (reporting bias) Unclear risk Protocol not available.
Other bias Unclear risk Funder: Nestle (manufacturer of the trial formula).
Raupp 1995
Methods RCT.
Participants Neonates, bodyweight 1000-1799 g.
Interventions Empirical use of partially hydrolysed whey-casein formula* (n = 56)
Non-hydrolysed preterm formula* (n = 52).
Outcomes Biochemistry.
Bone mineralisation.
Blood/serum.
Necrotising enterocolitis.
Notes University Children’s Hospital of Düsseldorf.
*Energy content of both formulas: 80 kCal/100 mL.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Information not available.
Allocation concealment (selection bias) Unclear risk Information not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unblinded.
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Raupp 1995 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Unblinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk All infants assessed for primary outcomes.
Selective reporting (reporting bias) Unclear risk Protocol not available.
Other bias Unclear risk Funder: Nestle (manufacturer of the trial formula).
Riezzo 2001
Methods RCT.
Participants Preterm infants (n = 36).
Interventions Partially hydrolysed casein preterm formula* (n = 18).
Standard (whey-casein) formula* (n = 18).
Outcomes Proportion of infants who had > 1 episode of regurgitation or vomiting per day
Notes Department of Pediatrics, Neonatology Section, University of Bari, Bari, Italy
Trial date: 2000.
Energy content of hydrolysed formula (80 kCal/100 mL) higher than control standard
term formula (68 kCal/100 mL). Because this did not report growth rates (the reason for
specifying similar energy levels in comparison formulas), we made a consensus decision
to include the trial
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Unclear evidence provided - only stated that infants were ran-
domly assigned
Allocation concealment (selection bias) Unclear risk Unclear evidence provided - only stated that infants were ran-
domly assigned
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unblinded.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Unblinded.
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Riezzo 2001 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All infants assessed for primary outcomes.
Selective reporting (reporting bias) Unclear risk Protocol not available.
Other bias Unclear risk Funder: not stated.
Schweizer 1993
Methods RCT.
Participants Preterm infants (formula fed).
Interventions Extensively hydrolysed whey-casein term formula (Alfare)* (n = 26)
Non-hydrolysed preterm formula (Prematil)* (n = 26).
Outcomes Time to regain birth weight.
Time to full enteral feeding.
Mean number of high gastric residual volumes per day.
Notes Kinderklinik der Stadt, Klinlken, Dortmund.
Trial date: 1991-1993.
* Energy content of hydrolysed formula (70 kCal/100 mL) lower than control standard
preterm formula (80 kCal/100 mL). Because this did not report growth rates (the rea-
son for specifying similar energy levels in comparison formulas), we made a consensus
decision to include the trial
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufﬁcient information - only abstract available.
Allocation concealment (selection bias) Unclear risk Insufﬁcient information - only abstract available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double-blinded.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Double-blinded.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcomes reported for all participants.
Selective reporting (reporting bias) Unclear risk Protocol not available.
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Schweizer 1993 (Continued)
Other bias Unclear risk Funder: not stated.
Szajewska 2004
Methods RCT.
Participants Preterm infants, bodyweight < 2500 g with ≥ 1 ﬁrst-degree relative with atopy
Interventions Extensively (n = 26) or partially hydrolysed whey-casein preterm formula* (n = 32)
Standard preterm formula* (n = 32).
Outcomes Allergic disease in infancy.
Feed intolerance.
Notes Primary aim to assess effects on allergy and atopic disease.
In hospital feed tolerance, growth or adverse outcomes not reported. We contacted
corresponding author to seek these data in December 2016
*Energy content of both formulas: 80 kCal/100 mL.
33% “dropout” prior to assessment at 4-5 months’ post-term.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised schedule generated - unspeciﬁed how.
Allocation concealment (selection bias) Low risk Sealed numbered envelopes - not stated if opaque, but codes
concealed from investigators until trial completed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Double-blind” but study and control formulas not identical in
texture and smell
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Double-blind” but study and control formulas not identical in
texture and smell
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcomes reported for all participants.
Selective reporting (reporting bias) Unclear risk Protocol not available.
Other bias Unclear risk Funded by Ovita Nutricia Research Foundation.
n: number of infants; RCT: randomised controlled trial.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Agosti 2003 Not an RCT.
Corvaglia 2013 Cross-over RCT with cross-over at each enteral feed.
Logarajaha 2015 Cross-over RCT with cross-over at 24 hours.
Mihatsch 1999 Cross-over RCT with initial formula allocation for 5 days only
Mihatsch 2001a Cross-over RCT with initial formula allocation for 5 days only
Rigo 1994 5-arm RCT with term infants receiving different types of hydrolysed formula (3 different whey hydrolysate
formulas, a soy-collagen hydrolysate formula, or a whey-casein hydrolysate formula)
Rigo 1995 Not an RCT.
RCT: randomised controlled trial.
Characteristics of studies awaiting assessment [ordered by study ID]
Del Moral 2017
Methods RCT (double blind).
Randomisation sequence was generated by computer, allocation by sealed envelopes
Participants Very low birth weight or very preterm infants (stratiﬁed by 2 birth weight categories (500-1000 g and 1001-1500 g)
) who survived > 3 days after birth and for whom breast milk was not available or insufﬁcient for requirements
Interventions Empirical use of 100% whey protein partially hydrolysed preterm formula (n = 62) vs intact preterm formula (n =
73)
Breast milk allowed if available and the different formulas were given to supplement when no breast milk available
(postrandomisation exclusion if breast milk > 25% of total enteral intake)
Outcomes Time to achieve full feeds.
Number of days from initiating oral feeds to achieve full feeds
Mortality.
Necrotising enterocolitis.
Notes Principal investigator: Teresa del Moral, Department of Pediatrics, Miller School of Medicine, University of Miami,
FL, USA
Contacted tdelmoral@miami.edu in July 2017 seeking data.
Trial date: 2004-2005.
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Del Moral 2017 (Continued)
Funded by Nestle.
Study discontinued because the increasingly common use of breast milk meant recruitment was much slower than
planned
Dobryanskyy 2015
Methods RCT.
Participants Very low birth weight (< 1500 g) infants.
Interventions Hydrolysed formula (n = 35) vs standard preterm formula (n = 25)
Outcomes Feed intolerance.
Time to full enteral feeding.
Necrotising enterocolitis.
9 additional infants (originally randomised) who died were excluded
Notes Article in Ukrainian. Awaiting translation.
Luo 2016
Methods RCT.
Participants “Very/extremely” low birth weight infants.
Interventions Hydrolysed protein formula vs preterm formula.
Outcomes Feed intolerance.
Growth rates.
Notes Article in Chinese. Awaiting translation.
RCT: randomised controlled trial.
Characteristics of ongoing studies [ordered by study ID]
ACTRN12613000481774
Trial name or title Effects of a New Hydrolyzed Powdered Formula on Feeding Tolerance in Preterm Neonates: a Randomised
Placebo-Controlled Study
Methods RCT.
Participants 60 newborns with birth weight <1500 g.
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ACTRN12613000481774 (Continued)
Interventions Powdered hydrolysed formula vs standard preterm formula.
Outcomes Time to reach full enteral feeding (120 kCal/kg/day).
Starting date 2013.
Contact information Prof Gianluca Terrin, University of Rome “La Sapienza”, Italy
Notes Trial has not proceeded due to lack of funding (personal communication from Prof Terrin)
Yin 2015
Trial name or title Extensively Hydrolyzed Milk Protein Formula in Preterm Children
Methods RCT.
Participants 370 preterm infants < 34 weeks’ gestational age who could not be breastfed
Interventions Extensively hydrolysed (100% whey protein) formula (66 kCal/100 mL) vs preterm formula (80 kCal/100
mL) fed until discharge from the neonatal intensive care unit
Outcomes Incidence of feed intolerance.
Time to achieve full enteral nutrition.
Starting date 2016.
Contact information Zhongda Hospital Southeast University, Nanjing, China.
Contacted lipingyin zd@163.com in November 2016 seeking data
Notes Registered with the Chinese Clinical Trial Registry (ChiCTR-IOR-14005696) in 2014
RCT: randomised controlled trial.
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D A T A A N D A N A L Y S E S
Comparison 1. Hydrolysed versus non-hydrolysed formula
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Feed intolerance 3 161 Risk Ratio (M-H, Fixed, 95% CI) 2.71 [0.29, 25.00]
2 Necrotising enterocolitis 5 385 Risk Difference (M-H, Fixed, 95% CI) 0.00 [-0.03, 0.04]
2.1 Partially hydrolysed 3 238 Risk Difference (M-H, Fixed, 95% CI) 0.01 [-0.03, 0.06]
2.2 Extensively hydrolysed 2 147 Risk Difference (M-H, Fixed, 95% CI) -0.02 [-0.07, 0.04]
3 Time to full enteral feeding 1 16 Mean Difference (IV, Fixed, 95% CI) -1.0 [-8.36, 6.36]
4 Weight gain (g/kg/day) 3 113 Mean Difference (IV, Fixed, 95% CI) -3.02 [-4.66, -1.38]
5 Length gain (mm/week) 2 97 Mean Difference (IV, Fixed, 95% CI) -0.04 [-1.24, 1.15]
6 Head circumference growth
(mm/week)
2 97 Mean Difference (IV, Fixed, 95% CI) 0.27 [-0.39, 0.94]
7 Serum alkaline phosphatase
(IU/L)
2 88 Mean Difference (IV, Fixed, 95% CI) 16.61 [-34.15, 67.
37]
8 Late-onset invasive infection 1 60 Risk Ratio (M-H, Fixed, 95% CI) 1.5 [0.27, 8.34]
9 Any allergic disease 1 63 Risk Ratio (M-H, Fixed, 95% CI) 0.62 [0.27, 1.42]
Analysis 1.1. Comparison 1 Hydrolysed versus non-hydrolysed formula, Outcome 1 Feed intolerance.
Review: Protein hydrolysate versus standard formula for preterm infants
Comparison: 1 Hydrolysed versus non-hydrolysed formula
Outcome: 1 Feed intolerance
Study or subgroup Hydrolysed Non-hydrolysed Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Baldassarre 2017 0/30 0/30 Not estimable
Florendo 2009 3/42 1/38 100.0 % 2.71 [ 0.29, 25.00 ]
Maggio 2005 0/10 0/11 Not estimable
Total (95% CI) 82 79 100.0 % 2.71 [ 0.29, 25.00 ]
Total events: 3 (Hydrolysed), 1 (Non-hydrolysed)
Heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours hydrolysed Favours non-hydrolysed
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Analysis 1.2. Comparison 1 Hydrolysed versus non-hydrolysed formula, Outcome 2 Necrotising
enterocolitis.
Review: Protein hydrolysate versus standard formula for preterm infants
Comparison: 1 Hydrolysed versus non-hydrolysed formula
Outcome: 2 Necrotising enterocolitis
Study or subgroup Hydrolysed Non-hydrolysed
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Partially hydrolysed
Florendo 2009 1/42 0/38 20.8 % 0.02 [ -0.04, 0.09 ]
Pauls 1996 1/25 1/25 13.0 % 0.0 [ -0.11, 0.11 ]
Raupp 1995 3/56 2/52 28.1 % 0.02 [ -0.06, 0.09 ]
Subtotal (95% CI) 123 115 61.8 % 0.01 [ -0.03, 0.06 ]
Total events: 5 (Hydrolysed), 3 (Non-hydrolysed)
Heterogeneity: Chi2 = 0.14, df = 2 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.61 (P = 0.54)
2 Extensively hydrolysed
Baldassarre 2017 0/30 0/30 15.6 % 0.0 [ -0.06, 0.06 ]
Mihatsch 2002 1/46 2/41 22.6 % -0.03 [ -0.11, 0.05 ]
Subtotal (95% CI) 76 71 38.2 % -0.02 [ -0.07, 0.04 ]
Total events: 1 (Hydrolysed), 2 (Non-hydrolysed)
Heterogeneity: Chi2 = 0.33, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.59 (P = 0.56)
Total (95% CI) 199 186 100.0 % 0.00 [ -0.03, 0.04 ]
Total events: 6 (Hydrolysed), 5 (Non-hydrolysed)
Heterogeneity: Chi2 = 1.06, df = 4 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.87)
Test for subgroup differences: Chi2 = 0.71, df = 1 (P = 0.40), I2 =0.0%
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Analysis 1.3. Comparison 1 Hydrolysed versus non-hydrolysed formula, Outcome 3 Time to full enteral
feeding.
Review: Protein hydrolysate versus standard formula for preterm infants
Comparison: 1 Hydrolysed versus non-hydrolysed formula
Outcome: 3 Time to full enteral feeding
Study or subgroup Hydrolysed Non-hydrolysed
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Picaud 2001 9 16 (8) 7 17 (7) 100.0 % -1.00 [ -8.36, 6.36 ]
Total (95% CI) 9 7 100.0 % -1.00 [ -8.36, 6.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.79)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Hydrolysed versus non-hydrolysed formula, Outcome 4 Weight gain (g/kg/day).
Review: Protein hydrolysate versus standard formula for preterm infants
Comparison: 1 Hydrolysed versus non-hydrolysed formula
Outcome: 4 Weight gain (g/kg/day)
Study or subgroup Hydrolysed Non-hydrolysed
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Florendo 2009 40 22.3 (3.5) 36 24 (7.1) 41.1 % -1.70 [ -4.26, 0.86 ]
Maggio 2005 10 17.4 (3.4) 11 20.5 (3.3) 32.7 % -3.10 [ -5.97, -0.23 ]
Picaud 2001 9 23.8 (4.3) 7 28.8 (2.1) 26.2 % -5.00 [ -8.21, -1.79 ]
Total (95% CI) 59 54 100.0 % -3.02 [ -4.66, -1.38 ]
Heterogeneity: Chi2 = 2.48, df = 2 (P = 0.29); I2 =19%
Test for overall effect: Z = 3.61 (P = 0.00031)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Hydrolysed versus non-hydrolysed formula, Outcome 5 Length gain (mm/week).
Review: Protein hydrolysate versus standard formula for preterm infants
Comparison: 1 Hydrolysed versus non-hydrolysed formula
Outcome: 5 Length gain (mm/week)
Study or subgroup Hydrolysed Non-hydrolysed
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Florendo 2009 40 10 (3) 36 10 (3) 77.8 % 0.0 [ -1.35, 1.35 ]
Maggio 2005 10 12.7 (2.7) 11 12.9 (3.2) 22.2 % -0.20 [ -2.73, 2.33 ]
Total (95% CI) 50 47 100.0 % -0.04 [ -1.24, 1.15 ]
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.07 (P = 0.94)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Hydrolysed versus non-hydrolysed formula, Outcome 6 Head circumference
growth (mm/week).
Review: Protein hydrolysate versus standard formula for preterm infants
Comparison: 1 Hydrolysed versus non-hydrolysed formula
Outcome: 6 Head circumference growth (mm/week)
Study or subgroup Hydrolysed Non-hydrolysed
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Florendo 2009 40 10 (2) 36 9 (2) 54.6 % 1.00 [ 0.10, 1.90 ]
Maggio 2005 10 9.4 (1.2) 11 10 (1.1) 45.4 % -0.60 [ -1.59, 0.39 ]
Total (95% CI) 50 47 100.0 % 0.27 [ -0.39, 0.94 ]
Heterogeneity: Chi2 = 5.50, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Hydrolysed versus non-hydrolysed formula, Outcome 7 Serum alkaline
phosphatase (IU/L).
Review: Protein hydrolysate versus standard formula for preterm infants
Comparison: 1 Hydrolysed versus non-hydrolysed formula
Outcome: 7 Serum alkaline phosphatase (IU/L)
Study or subgroup Hydrolysed Non-hydrolysed
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Florendo 2009 38 312 (122) 34 286 (111) 89.0 % 26.00 [ -27.82, 79.82 ]
Raupp 1995 7 430 (178) 9 489 (118) 11.0 % -59.00 [ -211.74, 93.74 ]
Total (95% CI) 45 43 100.0 % 16.61 [ -34.15, 67.37 ]
Heterogeneity: Chi2 = 1.06, df = 1 (P = 0.30); I2 =6%
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Hydrolysed versus non-hydrolysed formula, Outcome 8 Late-onset invasive
infection.
Review: Protein hydrolysate versus standard formula for preterm infants
Comparison: 1 Hydrolysed versus non-hydrolysed formula
Outcome: 8 Late-onset invasive infection
Study or subgroup Hydrolysed Non-hydrolysed Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Baldassarre 2017 3/30 2/30 100.0 % 1.50 [ 0.27, 8.34 ]
Total (95% CI) 30 30 100.0 % 1.50 [ 0.27, 8.34 ]
Total events: 3 (Hydrolysed), 2 (Non-hydrolysed)
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Hydrolysed versus non-hydrolysed formula, Outcome 9 Any allergic disease.
Review: Protein hydrolysate versus standard formula for preterm infants
Comparison: 1 Hydrolysed versus non-hydrolysed formula
Outcome: 9 Any allergic disease
Study or subgroup Hydrolysed Non-hydrolysed Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Szajewska 2004 8/39 8/24 100.0 % 0.62 [ 0.27, 1.42 ]
Total (95% CI) 39 24 100.0 % 0.62 [ 0.27, 1.42 ]
Total events: 8 (Hydrolysed), 8 (Non-hydrolysed)
Heterogeneity: not applicable
Test for overall effect: Z = 1.14 (P = 0.26)
Test for subgroup differences: Not applicable
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A P P E N D I C E S
Appendix 1. Electronic search strategy
Database: Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and
Ovid MEDLINE(R)
<1946 to present>
MEDLINE searched 5 May 2017; 453 records identified
--------------------------------------------------------------------------------
1 exp Infant, Newborn/ (561559)
2 Premature Birth/ (10039)
3 (neonat$ or neo nat$).ti,ab. (231791)
4 (newborn$ or new born$ or newly born$).ti,ab. (150586)
5 (preterm or preterms or pre term or pre terms).ti,ab. (60963)
6 (preemie$ or premie or premies).ti,ab. (142)
7 (prematur$ adj3 (birth$ or born or deliver$)).ti,ab. (13989)
8 (low adj3 (birthweight$ or birth weight$)).ti,ab. (30615)
9 (lbw or vlbw or elbw).ti,ab. (7084)
10 infan$.ti,ab. (388569)
11 (baby or babies).ti,ab. (62128)
12 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 (954384)
13 (hydroly$ adj3 (formula$ or milk or protein$ or whey)).ti,ab. (7903)
14 (hypoallergen$ adj3 (formula$ or milk or protein$ or whey)).ti,ab. (273)
15 (Nutramigen or Nutriprem or Pregestamil or Profylac or Nan or Aptamil Pepti or Pepti-Junior or Pepdite or Infatrini or Similac or
Gold Prem Pro or Alimentum).ti,ab. (1787)
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16 13 or 14 or 15 (9804)
17 randomized controlled trial.pt. (462115)
18 controlled clinical trial.pt. (94040)
19 randomized.ab. (403274)
20 placebo.ab. (188761)
21 drug therapy.fs. (1991821)
22 randomly.ab. (280150)
23 trial.ab. (422286)
24 groups.ab. (1725818)
25 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 (4099198)
26 exp animals/ not humans.sh. (4396754)
27 25 not 26 (3544583)
28 12 and 16 and 27 (453)
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
Database: Ovid Embase <1974 to 2017 week 18>
Searched via Ovid 5 May 2017 391 records identiﬁed
--------------------------------------------------------------------------------
1 exp Infant, Newborn/ (515450)
2 Premature Birth/ (48076)
3 (neonat$ or neo nat$).ti,ab. (286253)
4 (newborn$ or new born$ or newly born$).ti,ab. (176250)
5 (preterm or preterms or pre term or pre terms).ti,ab. (79839)
6 (preemie$ or premie or premies).ti,ab. (200)
7 (prematur$ adj3 (birth$ or born or deliver$)).ti,ab. (17865)
8 (low adj3 (birthweight$ or birth weight$)).ti,ab. (36327)
9 (lbw or vlbw or elbw).ti,ab. (9053)
10 infan$.ti,ab. (436861)
11 (baby or babies).ti,ab. (80736)
12 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 (1027154)
13 (hydroly$ adj3 (formula$ or milk or protein$ or whey)).ti,ab. (8679)
14 (hypoallergen$ adj3 (formula$ or milk or protein$ or whey)).ti,ab. (417)
15 (Nutramigen or Nutriprem or Pregestamil or Profylac or Nan or Aptamil Pepti or Pepti-Junior or Pepdite or Infatrini or Similac or
Gold Prem Pro or Alimentum).ti,ab. (1685)
16 13 or 14 or 15 (10503)
17 clinical trial/ (918094)
18 randomized controlled trial/ (442254)
19 randomization/ (73053)
20 single blind procedure/ (26265)
21 double blind procedure/ (136826)
22 crossover procedure/ (50503)
23 placebo/ (303176)
24 randomi?ed controlled trial$.tw. (153302)
25 rct.tw. (23420)
26 random allocation.tw. (1658)
27 randomly allocated.tw. (26937)
28 allocated randomly.tw. (2222)
29 (allocated adj2 random).tw. (858)
30 single blind$.tw. (19050)
31 double blind$.tw. (176511)
32 ((treble or triple) adj blind$).tw. (674)
33 placebo$.tw. (251481)
34 prospective study/ (366226)
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35 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 (1721674)
36 case study/ (45994)
37 case report.tw. (332856)
38 abstract report/ or letter/ (1009473)
39 36 or 37 or 38 (1380654)
40 35 not 39 (1677110)
41 12 and 16 and 40 (391)
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
Database: Maternity & Infant Care Database (MIDIRS) <1971 to March 2017>
Searched via Ovid 5 May 2017 20 records identified
1 (neonat$ or neo nat$).ti,ab. (37541)
2 (newborn$ or new born$ or newly born$).ti,ab. (17281)
3 (preterm or preterms or pre term or pre terms).ti,ab. (21945)
4 (preemie$ or premie or premies).ti,ab. (48)
5 (prematur$ adj3 (birth$ or born or deliver$)).ti,ab. (3526)
6 (low adj3 (birthweight$ or birth weight$)).ti,ab. (9603)
7 (lbw or vlbw or elbw).ti,ab. (2624)
8 infan$.ti,ab. (55675)
9 (baby or babies).ti,ab. (26173)
10 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 (103259)
11 (hydroly$ adj3 (formula$ or milk or protein$ or whey)).ti,ab. (144)
12 (hypoallergen$ adj3 (formula$ or milk or protein$ or whey)).ti,ab. (28)
13 (Nutramigen or Nutriprem or Pregestamil or Profylac or Nan or Aptamil Pepti or Pepti-Junior or Pepdite or Infatrini or Similac or
Gold Prem Pro or Alimentum).ti,ab. (33)
14 11 or 12 or 13 (188)
15 10 and 14 (178)
16 limit 15 to randomised controlled trial (20)
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
Database: CINAHL
Search date: 9 June 2017
Search ID# Search terms Search options
S1 (MH “Infant, Newborn+”) Search modes - Boolean/Phrase
S2 TX ( (neonat* or neo nat*) ) OR TX ( (newborn* or new
born* or newly born*) ) OR TX ( (preterm or preterms
or pre term or pre terms) ) OR TX ( (preemie$ or premie
or premies) ) OR TX ( (prematur* N3 (birth* or born
or deliver*)) ) OR TX ( (low N3 (birthweight* or birth
weight*)) ) ORTX ( (lbw or vlbw or elbw) )ORTX infan*
OR TX ( (baby or babies) )
Search modes - Boolean/Phrase
S3 S1 OR S2 Search modes - Boolean/Phrase
S4 TX ( (hydroly* N3 (formula* or milk or protein* or whey)
) ) OR TX ( (hypoallergen* N3 (formula* or milk or pro-
tein* or whey)) ) OR TX ( (Nutramigen or Nutriprem or
Pregestamil or Profylac or Nan or Aptamil Pepti or Pepti-
Search modes - Boolean/Phrase
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(Continued)
Junior or Pepdite or Infatrini or Similac or Gold Prem Pro
or Alimentum) )
S5 S3 AND S4 Search modes - Boolean/Phrase
S6 S3 AND S4 Limiters - Clinical Queries: Therapy - High Sensitivity
Search modes - Boolean/Phrase
(210 records)
Appendix 2. Risk of bias
• Random sequence generation: we categorised the method used to generate the allocation sequence as:
◦ low risk of bias: any random process (e.g. random number table; computer random number generator; coin tossing;
shufﬂing of cards or envelopes; throwing of dice; drawing of lots; minimisation (may be implemented without a random element; this
is considered equivalent to being random));
◦ high risk of bias: any non-random process (e.g. sequence generated by odd or even date of birth; date (or day) of admission;
sequence generated by hospital or clinic record number; allocation by judgement of the clinician; allocation by preference of the
participant; allocation based on results of a laboratory test or series of tests; allocation based on availability of the intervention);
◦ unclear risk of bias: insufﬁcient information about the sequence generation process to permit judgement.
• Allocation concealment: we categorised the method used to conceal the allocation sequence as:
◦ low risk of bias: randomisation method described that would not allow investigator/participant to know or inﬂuence the
intervention group before eligible participants entered the study (i.e. central allocation, including telephone, web-based, and
pharmacy-controlled randomisation; sequentially numbered drug containers of identical appearance; sequentially numbered, opaque,
sealed envelopes);
◦ high risk of bias: open random allocation schedule (i.e. list of random numbers); assignment envelopes used without
appropriate safeguards (e.g. if envelopes were unsealed or non-opaque or were not sequentially numbered); alternation or rotation;
date of birth; case record number; any other explicitly unconcealed procedure;
◦ unclear risk of bias: randomisation stated but no information provided on method used.
• Blinding of participants and personnel: we assessed blinding of participants, clinicians and carers, and outcome assessors
separately for different outcomes and categorised the methods as:
◦ low risk of bias: no blinding or incomplete blinding, but review authors judged that the outcome was not likely to be
inﬂuenced by lack of blinding; blinding of participants and key study personnel ensured, and unlikely that blinding could have been
broken;
◦ high risk of bias: no blinding or incomplete blinding, and the outcome was likely to be inﬂuenced by lack of blinding;
blinding of key study participants and personnel attempted, but likely that blinding could have been broken, and the outcome was
likely to be inﬂuenced by lack of blinding;
◦ unclear risk of bias: insufﬁcient information to permit judgement.
• Incomplete outcome data: we described the completeness of data including attrition and exclusions from the analysis for each
outcome and any reasons for attrition or exclusion where reported. We assessed whether missing data were balanced across groups or
were related to outcomes. We categorised completeness as:
◦ low risk of bias: no missing outcome data; reasons for missing outcome data unlikely to be related to true outcome (for
survival data, censoring unlikely to introduce bias); missing outcome data balanced in numbers across intervention groups, with
similar reasons for missing data across groups; for dichotomous outcome data, the proportion of missing outcomes compared with
observed event risk not enough to have a clinically relevant impact on the intervention effect estimate; for continuous outcome data,
plausible effect size (difference in means or standardised difference in means) among missing outcomes not sufﬁcient to have a
clinically relevant impact on observed effect size; missing data imputed by appropriate methods;
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◦ high risk of bias: reason for missing outcome data likely to be related to true outcome, with imbalance in numbers or
reasons for missing data across intervention groups; for dichotomous outcome data, the proportion of missing outcomes compared
with observed event risk enough to induce clinically relevant bias in intervention effect estimate; for continuous outcome data,
plausible effect size (difference in means or standardised difference in means) among missing outcomes enough to induce clinically
relevant bias in observed effect; ’as-treated’ analysis done with substantial departure of the intervention received from that assigned at
randomisation; potentially inappropriate application of simple imputation;
◦ unclear risk of bias: insufﬁcient information to permit judgement.
• Selective reporting: we assessed reporting bias due to selective outcome reporting as:
◦ low risk of bias: study protocol was available, and all the study’s prespeciﬁed (primary and secondary) outcomes that were of
interest in the review were reported in the prespeciﬁed way; study protocol was not available, but it was clear that published reports
included all expected outcomes, including those that were prespeciﬁed;
◦ high risk of bias: not all the study’s prespeciﬁed primary outcomes were reported; one or more primary outcomes were
reported by measurements, analysis methods or subsets of data (i.e. subscales) that had not been prespeciﬁed; one or more reported
primary outcomes were not prespeciﬁed (unless clear justiﬁcation for their reporting was provided, such as an unexpected adverse
effect); one or more outcomes of interest in the review had been reported incompletely, so that they could not be entered into a meta-
analysis; the study report failed to include results for a key outcome that would be expected to have been reported for such a study;
◦ unclear risk of bias: insufﬁcient information to permit judgement.
• Other bias: we analysed bias due to problems not covered elsewhere in the table:
◦ low risk of bias: study appeared free of other sources of bias;
◦ high risk of bias: study had a potential source of bias related to the speciﬁc study design used; stopped early because a data-
dependent study design was used; stopped early as the result of a data-dependent process (including a formal stopping rule); had
extreme baseline imbalance; was claimed to be fraudulent; had some other problem;
◦ unclear risk of bias: insufﬁcient information to assess whether an important risk of bias existed; insufﬁcient rationale or
evidence to suggest that an identiﬁed problem would introduce bias.
Appendix 3. GRADE
GRADE considers that evidence from randomised controlled trials is ’high’ quality but that assessment may be downgraded based on
consideration of any of ﬁve areas:
• design (risk of bias);
• consistency across studies;
• directness of the evidence;
• precision of estimates; and
• presence of publication bias.
This results in an assessment of the quality of a body of evidence in one of four grades:
• High: we are very conﬁdent that the true effect lies close to that of the estimate of the effect.
• Moderate: we are moderately conﬁdent in the effect estimate: the true effect is likely to be close to the estimate of the effect, but
there is a possibility that it is substantially different.
• Low: our conﬁdence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
• Very low: we have very little conﬁdence in the effect estimate: the true effect is likely to be substantially different from the
estimate of effect.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Two trials compared formulas with different energy densities (Schweizer 1993; Riezzo 2001). These did not report growth rates (the
reason for prespecifying similar energy levels) so we made consensus decision to include them in the review.
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